Radiotherapy and short-term androgen deprivation for localized prostate cancer.

@article{Jones2011RadiotherapyAS,
  title={Radiotherapy and short-term androgen deprivation for localized prostate cancer.},
  author={Christopher U. Jones and Daniel P. Hunt and David G. McGowan and Mahul B. Amin and Michael P. Chetner and Deborah Watkins Bruner and Mark H. Leibenhaut and Siraj Husain and Marvin Z Rotman and Luis Souhami and Howard M. Sandler and William U. Shipley},
  journal={The New England journal of medicine},
  year={2011},
  volume={365 2},
  pages={
          107-18
        }
}
BACKGROUND It is not known whether short-term androgen-deprivation therapy (ADT) before and during radiotherapy improves cancer control and overall survival among patients with early, localized prostate adenocarcinoma. METHODS From 1994 through 2001, we randomly assigned 1979 eligible patients with stage T1b, T1c, T2a, or T2b prostate adenocarcinoma and a prostate-specific antigen (PSA) level of 20 ng per milliliter or less to radiotherapy alone (992 patients) or radiotherapy with 4 months of… 

Figures and Tables from this paper

Impact of the duration of hormonal therapy following radiotherapy for localized prostate cancer.

It is determined that ADT for ≥36 months combined with EBRT significantly improved the progression-free survival of patients with high-risk localized prostate cancer and exhibited an acceptable toxicity profile.

Effects of dose-escalated radiotherapy in combination with long-term androgen deprivation on prostate cancer.

It is suggested that dose escalations result in significant improvements in bDFS, even when used in combination with long-term ADT, and clinical relapse-free survival (cRFS) and overall survival (OS) is similar between the two groups.

The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk prostate cancer: effects of radiation dose escalation

ADT reduced the risk of biochemical failure and distant metastasis in both low- and high dose radiation groups among men with intermediate-risk PCa, and increasing the duration of ADT beyond 6 months did not reduce therisk of biochemical failures.

Is neoadjuvant androgen deprivation therapy beneficial in prostate cancer treated with definitive radiotherapy?

NADT prior to definitive radiotherapy did not result in significant benefit in terms of BCRFS and OS, and NADT should not be performed routinely in the era of dose-escalated radiotherapy.

Impact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation

In conclusion, DERT with 78 Gy yields good disease control and low rate of pelvic nodal recurrence and ADT improves disease-free survival in patients with high-risk but not intermediate-risk disease.

Combined Androgen Blockade in Localized Prostate Cancer Treated With Definitive Radiation Therapy.

In men receiving definitive RT for intermediate- or high-risk PCa, CAB was not associated with improved PCSM or OS compared with GnRH alone, and long-term versus short-term GnRH-A therapy was associated withimproved PCSM and overall survival.

Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.

  • T. PisanskyD. Hunt H. Sandler
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2015
Extending AS duration from 8 weeks to 28 weeks before radiotherapy did not improve outcomes and a lower than expected prostate cancer death rate reduced ability to detect a between-group difference in disease-specific survival.

Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991.

  • M. BollaP. Maingon L. Collette
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016
Six months of concomitant and adjuvant AS improves biochemical and clinical DFS of intermediate- and high-risk cT1b-c to cT2a (with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread) prostatic carcinoma, treated by radiation.
...

References

SHOWING 1-10 OF 41 REFERENCES

Duration of androgen suppression in the treatment of prostate cancer.

The combination of radiotherapy plus 6 months of androgen suppression provides inferior survival as compared with radiotherapyplus 3 years of androgens suppression in the treatment of locally advanced prostate cancer.

Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

  • M. RoachK. Bae M. Pilepich
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
The addition of 4 months of ADT to EBRT appears to have a dramatic impact on clinically meaningful end points in men with locally advanced disease with no statistically significant impact on the risk of fatal cardiac events.

Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.

The addition of 6 months of AST to RT resulted in increased overall survival in men with localized but unfavorable-risk prostate cancer, and this result may pertain only to men without moderate or severe comorbidity.

Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.

Adjuvant treatment with goserelin, when started simultaneously with external irradiation, improves local control and survival in patients with locally advanced prostate cancer.

Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study.

There are important differences in urinary, bowel, and sexual functions over 2 years after different treatments for clinically localized prostate cancer and these outcome differences reflect treatment delivered to a heterogeneous group of patients in diverse health care settings.